Resilience to manufacture BridgeBio’s lead investigational gene therapy treatments, BBP-631 and BBP-812 Partnership provides an innovative, capital efficient, sustainable model for BridgeBio to develop, test and deliver transformative medicines for patients more quickly PALO ALTO, Calif. and SAN DIEGO, Oct.

弹性制造BridgeBio的主要研究性基因治疗，BBP-631和BBP-812合作伙伴关系为BridgeBio提供了一种创新，资本高效，可持续的模式，可以更快地为患者开发，测试和提供转化药物加利福尼亚州帕洛阿尔托和圣地亚哥，Oct。

03, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration to manufacture and advance BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease, and BBP-631, an investigational AAV 5 gene therapy for congenital adrenal hyperplasia (CAH).

032023（GLOBE NEWSWIRE）-BridgeBio Pharma，Inc。（BridgeBio），一家专注于遗传疾病和癌症的商业阶段生物制药公司，以及National Resilience，Inc。（Resilience），一家专注于技术的生物制造公司今天宣布了制造和推进BBP-812的战略合作，用于Canavan病的研究性腺相关病毒（AAV）9基因疗法和用于先天性肾上腺增生（CAH）的研究性AAV 5基因疗法BBP-631。

The two companies have developed a novel manufacturing and aligned incentive business model to drive these gene therapies forward with an emphasis on sustainability and capital-efficiency. Under the terms of the collaboration, BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites.

这两家公司开发了一种新颖的制造和协调激励商业模式，以推动这些基因疗法的发展，重点是可持续性和资本效率。根据合作条款，BridgeBio将其基于AAV的主要基因治疗候选药物的制造过程转移到Resilience的基因治疗网站网络。

As part of an innovative cost and risk-sharing framework, Resilience will provide in-kind manufacturing services and will receive future development and approval milestones and low-to-mid single digit royalties on BBP-631 and BBP-812. Resilience will support the ongoing clinical development manufacturing needs and will serve as the primary commercial manufacturer for both programs if successful.

作为创新成本和风险分担框架的一部分，弹性将提供实物制造服务，并将获得未来的开发和批准里程碑以及BBP-631和BBP-812的中低位数版税。弹性将支持持续的临床开发制造需求，并且如果成功，将作为两个计划的主要商业制造商。

“Our partnership with BridgeBio seeks to accelerate development of innovative therapeutic options for patients in need,” said Rahul Singhvi, Sc.D., Chief Executive Office.

首席执行办公室Rahul Singhvi博士说：“我们与BridgeBio的合作旨在加速为有需要的患者开发创新的治疗方案。